Droplet Digital™ PCR – Powering the Future

Bio-Rad Laboratories, Inc.

NYSE: BIO and BIO.B

August 26, 2025

Safe Harbor

Forward-Looking Statements.
Some statements in this presentation and the related webinar and Q&A session may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management's goals, plans, and expectations, our future financial performance, our future financial projections, our strategy, our products, our expectations regarding our products, and other matters. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "anticipate," "believe," "expect," "assume," "continue," "may," "will," "intend," "estimate," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Our actual results may differ materially from these plans and expectations. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in our public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Additional Disclosures.
The data included in this presentation and the related webinar and Q&A session regarding the industry in which we operate, including the size of certain total addressable markets, are based on publicly available information and published industry sources. In presenting this information, we have also made certain estimates and assumptions that we believe to be reasonable based on the information referred to above and similar sources, as well as our internal research, calculations and assumptions based on our analysis of such information and our knowledge of, and our experience to date in, our industries and markets. Such data is subject to change and may be limited by the availability of raw data, the voluntary nature of the data gathering process and other limitations inherent in any statistical survey. Accordingly, you are cautioned not to place undue reliance on such data or any other such estimates. While we believe such information is reliable, we cannot guarantee the accuracy or completeness of this information.

Agenda

01 Digital PCR Technology

02 Segment Growth Drivers

03 Bio-Rad’s Digital PCR Portfolio

04 Powering the Future of Digital PCR

The Evolution of PCR to Digital PCR



PCR
Qualitative

Democratized the study of DNA

Accelerated the biotech industry

Backbone of the human genome project



qPCR
Relative Quantification

Made PCR quantitative

Revolutionized the study of gene expression profiling

Transformed molecular Dx



dPCR
Absolute Quantification

Absolute quantification of nucleic acids

Enables rare-event applications like liquid biopsies

Bio-Rad's Innovation in Digital PCR

2010

Bio-Rad Commercializes Digital PCR

QX100™ Droplet Digital™ PCR System establishes a new standard in absolute quantitation

Diagnostic Registration

First FDA-Cleared and CE-IVD Registered dPCR System and Diagnostic Test

Absolute Accuracy

First dPCR System to deliver precision *and* accuracy, backed by metrological standards

Application Expansion

Novel digital PCR tests to enable customers in cell and gene therapy

2025

Bio-Rad Continues to Lead the Way

12,000+ Peer-Reviewed Publications, Best Performance & Breadth of Menu

BIO-RAD

Droplets are the Benchmark for Precision, Sensitivity, and Reproducibility



Our droplet-based approach delivers the highest quality data

- Droplets are **highly uniform** in size and volume, resulting in greater precision
- Droplets are **highly reproducible** in size and volume across instruments and labs
- Droplets are **flexible**, enabling limitless scalability and volumes to suit any application

Droplet Digital™ PCR provides "unprecedented levels of precision, accuracy and resolution for quantification of nucleic acids"

Pinheiro LB, O'Brien H, Druce J, et al. Interlaboratory reproducibility of droplet digital polymerase chain reaction using a new DNA reference material format. Anal Chem. 2017;89(21):11243-11251.

BIO-RAD

Droplets Enable Applications that Save Lives

Our droplet-based approach delivers the highest quality data

Oncology

Liquid biopsy requires **sensitivity**

Monitoring requires **precision** and **reproducibility**

Biopharma Production

Dose control requires **accuracy**

Contaminant testing requires **sensitivity** and **reproducibility**

Bio-Surveillance

Monitoring wastewater requires **reproducibility**

Simple workflow is required for practical deployment

Drivers of Absolute Quantitation Segment Growth are Evolving



As Customer Needs Evolve, Solutions Must Advance

Targeted Sequencing (NGS)

Advantages:

- High Multiplexing
- Discovery Tool

Challenges:

- Lower sensitivity
- Long time to result
- High cost
- Complex workflow & data interpretation

Targeted Sequencing Segment
~$2.4B[1]

Quantitative PCR (qPCR)

Advantages:

- Low cost
- Fast results

Challenges:

- Lower sensitivity
- Variability of results
- Relative measurements
- Standard curves

Relative Quantitation Segment
~$2.7B[1]

Droplet Digital™ PCR Meets Evolving Customer Needs

Targeted Sequencing (NGS)

Challenges create opportunities for ddPCR™ solutions



Quantitative PCR (qPCR)

Challenges create opportunities for ddPCR™ solutions

Droplet Digital™ PCR enables **rare allele detection, precise CNV quantification, absolute quantification without standards, and residual disease/viral reservoir monitoring**, all of which are not reliably achievable with other technologies

Bio-Rad Platforms Power the Entire Digital PCR Applications Without Compromise

Existing Bio-Rad Portfolio

QX200™, QX600™, QX ONE™ and QXDx™ ddPCR™ platforms

Supported by highly experienced Applications, Support and Service teams

Trusted customer choice in Biopharma, Oncology & Diagnostics

QX Continuum™ Platform

Simplest, qPCR-like workflow available

Lowest running cost available

From 1 to 96 samples without compromising performance

QX700™ Series Platform

Integrated workflow with **highest multiplexing** on the market

Scalable throughput and flexible protocols

Capable of growing with laboratory needs

✓ IVD ✓ CE-IVD ✓ 21 CFR

Positioning of Bio-Rad ddPCR™ Platforms

High Performance
Academic / Translational

QX600™

QX700™ S

BioPharma QA/QC

QX700™ HT

QX ONE™

Entry Level
Academic / Translational

QX700™ E

QX Continuum™

Clinical/LDT Labs

QXDx™

QX600Dx™

Our Industry Leading Assay Catalog Fuels Growth & Technology Conversion

Bio-Rad Maintains a catalog of over 490,000 assays for the research community

High Value Tests

in oncology, cell & gene therapy, and public health

Powerful Design Algorithms

and expert design services to advance scientific discoveries

External Partnerships

to expand the clinical assay menu globally

Our Industry Leading Assay Catalog - By the Numbers

34,000+
Validated Mutation Detection Assays

12,500+
Validated Copy Number Assays

445,000+
Validated Gene Expression Assays

50+
Infectious Disease Assays

60+
Validated Assays for Cell & Gene Therapy

50+
Methylation Detection Assays

~600,000 Assays Designed for qPCR and Compatible with ddPCR™ Systems

Allows customers to seamlessly move to digital PCR with their favorite assay

Peer-Reviewed Publications Demonstrate Value of Bio-Rad's Droplet Digital™ PCR[2]



Primary research articles continue to account for the majority of publications

There is a **strong shift** from method development towards clinical applications

Powering the Future of Digital PCR

Superior, Foundational Technology

- Digital PCR technology and market innovator since 2010
- Droplet partitioning independently verified as providing “unprecedented” levels of analytical capability



Digital PCR Expertise

- Over 12,000 clinical and research publications, doubled since 2021
- Dedicated, knowledgeable global digital PCR sales and support teams



Positioned to Capture Future Growth

- We will continue to grow our existing business and accelerate customer shift from qPCR and NGS to Droplet Digital™ PCR
- More than 490,000 validated, catalog assays and kits

Droplet Digital™ PCR - Powering the Future

Sources and Citations

1. Absolute Quantitation segment sizing based on Bio-Rad internal data comprised of primary and secondary research; July 2025.
2. Peer-reviewed primary research publications and review articles utilizing Bio-Rad Droplet Digital™ PCR Systems from 2012-2024. Bio-Rad internal data based on PubMed, Google Scholar and other sources of published literature. Data accessed August 2025.